COUMADIN Drug Patent Profile
✉ Email this page to a colleague
When do Coumadin patents expire, and when can generic versions of Coumadin launch?
Coumadin is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in COUMADIN is warfarin sodium. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the warfarin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Coumadin
A generic version of COUMADIN was approved as warfarin sodium by BARR on March 26th, 1997.
Summary for COUMADIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 134 |
Clinical Trials: | 132 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for COUMADIN |
Drug Sales Revenues: | Drug sales revenues for COUMADIN |
What excipients (inactive ingredients) are in COUMADIN? | COUMADIN excipients list |
DailyMed Link: | COUMADIN at DailyMed |
Recent Clinical Trials for COUMADIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Laval University | Phase 2 |
Helm Vision Group | Phase 1 |
Mirati Therapeutics Inc. | Phase 1 |